The Asia Pacific AI in Oncology Market was valued at $550.6 Million in 2024 and projected to reach to $2741.2 Million by 2029, representing a compound annual growth rate of 30.7%. The Asia Pacific AI in Oncology market is positioned for exceptional growth, expanding from USD 550.6 million in 2024 to USD 2,741.2 million by 2029.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific's AI in Oncology market is growing at 30.7% CAGR, outpacing the global rate of 29.4%, driven by increasing cancer prevalence and healthcare digitalization across the region.
China (USD 869.7M) and India (USD 463.3M) are key growth engines, leveraging large patient populations, expanding healthcare infrastructure, and government support for AI adoption in cancer care.
Japan represents a mature AI oncology market at USD 858.7M, with strong adoption of precision medicine, robotic surgery integration, and AI-driven diagnostic tools in established healthcare systems.
Rising healthcare expenditure, government initiatives, and partnerships between tech companies and hospitals are accelerating AI implementation in diagnosis, treatment planning, and drug discovery across Asia Pacific.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DEEP LEARNING (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 29.4% from 2024 to 2029 |
| Largest Segment | SOLID TUMORS (Cancer Type) |
| Market Size Base Year (Billions) | ~USD 2.45 (2024) |
| Revenue Forecast (Billions) | ~USD 8.9 (2029) |
| Segments Covered | Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model |
7 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| China | USD 869.7 Million |
| India | USD 463.3 Million |
| Japan | USD 858.7 Million |
| Rest Of Asia Pacific | USD 549.5 Million |
The Asia Pacific AI in Oncology Market was valued at USD 550.6 million in 2024 and is expected to grow to USD 2,741.2 million by 2029.
Asia Pacific's AI in Oncology Market is projected to grow at a compound annual growth rate (CAGR) of 30.7% from 2024 to 2029.
Major growth drivers in Asia Pacific include China, India, Japan, and South Korea, which are investing heavily in healthcare digitalization and AI-enabled cancer care solutions.
Key applications in Asia Pacific include diagnostic imaging analysis, treatment planning optimization, drug discovery acceleration, and personalized medicine development for cancer patients.
Asia Pacific's growth is driven by rising cancer incidence, government support for digital health, healthcare infrastructure investments, and increasing partnerships between technology companies and oncology institutions.
The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.
This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.
After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.
AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.
Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:
Full forecast, segment splits, and company analysis for all AI in Oncology Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report